|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary Table 1.** Potential predictors of HA-BSI during the COVID-period,-sample, according to BC results (N=7502) | | | | |
|  | **Univariable analysis** | | | **Multivariable analysis** |
|  | **Positive BCs**  **(N=1207)** | **Negative BCs**  **(N=6295)** | **OR (95% CI); p** | **OR (95% CI); p** |
| **Age (yrs.)** | 70 (59-78) | 67 (54-77) | **1.01 (1.00; 1.01); <0.001** | **1.01 (1.00; 1.01); <0.001** |
| **Female Sex** | 476 (39.4) | 2756 (43.8) | **0.84 (0.74; 0.95); 0.005** | 0.95 (0.30; 1.09); 0.465 |
| **COVID+** | 276 (22.9) | 927 (14.7) | **1.72 (1.48; 2.00); <0.001** | 1.14 (0.96; 1.35); 0.132 |
| **Days of hospitalization** | 26 (17-43) | 12 (7-21) | **1.04 (1.03; 1.05); <0.001** | **1.04 (1.03; 1.04); <0.001** |
| **ICU** | 240 (19.9) | 742 (11.8) | **1.86 (1.58; 2.18); <0.001** | **1.39 (1.16; 1.67); <0.001** |
| **Comorbidities** |  |  |  |  |
| *Diabetes* | 241 (20.0) | 1119 (17.8) | *1.15 (0.99; 1.35); 0.071* | 1.04 (0.88; 1.24); 0.614 |
| *Immune depression* | 204 (16.9) | 1170 (18.6) | 0.89 (0.76; 1.05); 0.166 |  |
| *Neurological disorders* | 237 (19.6) | 1085 (17.2) | **1.17 (1.00; 1.37); 0.045** | *0.85 (0.72; 1.02); 0.082* |
| *Neoplasms* | 516 (42.8) | 2591 (41.2) | 1.07 (0.94; 1.21); 0.304 |  |
| *Kidney failure* | 294 (24.4) | 995 (15.8) | **1.71 (1.48; 1.99); <0.001** | **1.71 (1.46; 2.01); <0.001** |
| **Abbreviations**: positive and negative BCs: blood cultures that were positive and negative for HA-BSI; COVID: COronaVIrus Disease; ICU: intensive care unit; OR: odds ratio; CI: confidence interval; HA-BSI: hospital-acquired bloodstream infection  Descriptive statistics are expressed as median (interquartile range: IQR) for quantitative data, as absolute and relative percentage frequencies for qualitative variables. In bold significant findings (p<0.05), in italic the suggestive ones (0.05≤p<0.10). | | | | |